Sign In
Buy VERV
$11.13
+0 (+0%)
At Close: Oct 24, 2025
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
07:00am, Wednesday, 29'th Jan 2025
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Compa
Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last?
10:36am, Thursday, 23'rd Jan 2025
Verve Therapeutics (VERV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength d
NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Compa
NEW YORK CITY, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Compa
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Shareholders to Connect
10:00am, Wednesday, 15'th Jan 2025
NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company")
NEW YORK CITY, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company")
NEW YORK CITY, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (
NEW YORK CITY, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 03'rd Jan 2025
BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December 31, 2024
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Investors to Connect
10:00am, Thursday, 02'nd Jan 2025
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDA
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Stockholders to Connect
10:00am, Sunday, 29'th Dec 2024
NEW YORK CITY, NY / ACCESSWIRE / December 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company")
NEW YORK CITY, NY / ACCESSWIRE / December 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company")
NEW YORK CITY, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company")
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Investors to Inquire about Securities Investigation
10:00am, Wednesday, 18'th Dec 2024
NEW YORK CITY, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company")
